Secondary Prophylaxis |
Disseminated, Non-Ocular Infection or GI Infection Caused by Microsporidia Other Than E. Bieneusi or V. Corneae:
Ocular Infection:
Topical fumagillin bicyclohexylammonium (Fumidil B) 3 mg/mL in saline (fumagillin 70 μg/mL) eye drops: 2 drops every 2 hours for 4 days, then 2 drops QID (investigational use only in United States) plus albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily for management of systemic infection
|
N/A |
Criteria For Discontinuing Secondary Prophylaxis:
Continue until sustained immune reconstitution (more than 6 months at CDC immunologic category 1 or 2), or
After initiation of cART and resolution of signs and symptoms
|
Treatment |
Effective cART Therapy:
For Disseminated (Not Ocular) and Intestinal Infection Attributed to Microsporidia Other Than E. bieneusi or V. corneae:
Treatment Duration:
For E. bieneusi or V. corneae infections:
Fumagillin adult dose 20 mg by mouth 3 times daily, or
TNP-470 (a synthetic analogue of fumagillin) recommended for treatment of infections due to E. bieneusi in HIV-infected adults
For Ocular Infection:
Topical fumagillin bicyclohexylammonium (Fumidil B) 3 mg/mL in saline (fumagillin 70 μg/mL) eye drops: 2 drops every 2 hours for 4 days, then 2 drops QID (investigational use only in United States) plus albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily for management of systemic infection
Treatment Duration:
|
N/A |
Supportive care: Hydration, correct electrolyte abnormalities, nutritional support
Fumagillin for systemic use is unavailable in the United States and data on dosing in children are unavailable. Consultation with an expert is recommended.
|